Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

11 Dec 2018

Abstract excerpt

Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3–5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review, we will summarize clinical trials of chemotherapy and PARP inhibitors (PARPi), alone or in combination, at the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30544963
DOI: 10.3390/cancers10120506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?PMID 30544963Read ↗

Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatmentSemantic proximity Read ↗

Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for <i>BRCA1/2</i>-Associated CancersSemantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

An overview of the research progress of BRCA gene mutations in breast cancer.Semantic proximity Read ↗

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer TreatmentSemantic proximity Read ↗

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and BeyondSemantic proximity Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

Targeting the DNA repair pathway for breast cancer therapy: Beyond the molecular subtypesSemantic proximity Read ↗

‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancerSemantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].Semantic proximity Read ↗

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.